Abstract:Targeted brain tumor therapy by nanoparticles (NPs) remains a daunting challenge due to the difficulty for NPs to go through the blood-brain barriers (BBB) and blood-brain tumor barriers (BBTB). In addition, Dactolisib (Dac) is an effective dual PI3K/mTOR inhibitor for cancer treatment. It was the first PI3K inhibitor to enter clinical trials but exhibited toxicity to normal tissues if not delivered to tumor sites by a tumor-targeting carrier. To explore Dac for glioblastoma (GBM) therapy while avoiding its toxicity, we developed a new brain tumor-targeting drug delivery system self-assembled from zein, a cell membrane-penetrating amphiphilic protein originally present in corn. Specifically, the amphiphilicity of zein drove it to self-assemble into NPs that encapsulated Dac with high efficiency. RVG29, a 29-mer brain-targeting peptide, was chemically conjugated to zein constituting the NPs, forming Dac-encapsulated NPs (zein-RVG-Dac_NPs). In vitro assays were conducted to verify the capability of the NPs in penetrating BBB/BBTB, targeting GBM cancer cells and killing them. ELISA was employed to assess the expression of nicotinic acetylcholine receptors (nAChR) on the cancer cells to understand the mechanism of cancer cell membrane penetration by the NPs. The NPs were intravenously injected into orthotopic GBM mice models to demonstrate the brain tumor targeting as well as the effective GBM therapy due to the targeted delivery of Dac to brain tumors. The treated tumors were immunohistochemically analyzed to verify the tumor destruction. To confirm the biosafety of the NPs in treating GBM, we also histopathologically evaluated the major normal organs and chemically analyzed the blood biomarkers. We found that a combination of zein and RVG29 facilitated the zein-RVG-Dac_NPs to cross the BBB/BBTB and became uptaken by the GBM cells through the nAChR-mediated pathways, enabling the NPs to cross BBB/BBTB and deliver Dac selectively to GBM cells. Hence, administration of the NPs through tail veins significantly increased the accumulation of Dac in the orthotopic brain tumor of mice and effectively inhibited tumor growth. Neither toxicity nor adverse effects in the major organs were found due to the excellent biocompatibility of zein and the targeted delivery of Dac into brain tumor cells. Hence, integrating a cancer cell-penetrating natural protein (zein) and a brain-targeting peptide (RVG29) can form NPs that can effectively penetrate BBB/BBTB and then enter brain tumor cells to release Dac, leading to highly effective targeted brain cancer therapy. Such NPs can be extended to the development of therapeutics for treating different brain diseases due to their unique combination of biocompatibility and brain-targeting capability.

Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles.

Brain-targeting Gene Delivery and Cellular Internalization Mechanisms for Modified Rabies Virus Glycoprotein RVG29 Nanoparticles.

Targeted Transport of Nanocarriers into Brain for Theranosis with Rabies Virus Glycoprotein-Derived Peptide

Borneol and Poly (ethylene Glycol) Dual Modified BSA Nanoparticles As an Itraconazole Vehicle for Brain Targeting

Targeting Small Molecule Delivery to the Brain and Spinal Cord via Intranasal Administration of Rabies Virus Glycoprotein (RVG29)-Modified PLGA Nanoparticles

Development and evaluation of novel itraconazole-loaded intravenous nanoparticles.

RVG29-modified Docetaxel-Loaded Nanoparticles for Brain-Targeted Glioma Therapy

Targeted Brain Delivery of RVG29‐modified Rifampicin‐loaded Nanoparticles for Alzheimer's Disease Treatment and Diagnosis

RVG Peptide-Functionalized Favipiravir Nanoparticle Delivery System Facilitates Antiviral Therapy of Neurotropic Virus Infection in a Mouse Model.

Targeted Delivery of Large Fusion Protein into Hippocampal Neurons by Systemic Administration.

Targeted Delivery of Proteins into the Central Nervous System Mediated by Rabies Virus Glycoprotein-Derived Peptide

Brain-targeted Delivery of PEGylated Nano-Bacitracin A Against Penicillin-sensitive and -Resistant Pneumococcal Meningitis: Formulated with RVG29 and Pluronic® P85 Unimers

A Combination Of Receptor Mediated Transcytosis And Photothermal Effect Promotes Bbb Permeability And The Treatment Of Meningitis Using Itraconazole

Advances of polypeptide fragment of rabiesvirus glycoprotein as a brain-targeting carrier

Efficient Anti-Glioma Therapy Through the Brain-Targeted RVG15-Modified Liposomes Loading Paclitaxel-Cholesterol Complex

Targeted Glioblastoma Therapy by Integrating Brain-Targeting Peptides and Corn-derived Cancer Cell-Penetrating Proteins into Nanoparticles to Cross Blood-Brain Tumor Barriers

Production and Characterization of a Fusion Peptide Derived from the Rabies Virus Glycoprotein (RVG29).

RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the brain.

Paclitaxel-loaded dextran nanoparticles decorated with RVG29 peptide for targeted chemotherapy of glioma: an <i>in vivo</i> study

A Brain-Vectored Angiopep-2 Based Polymeric Micelles for the Treatment of Intracranial Fungal Infection

Aptamer and RVG Functionalized Gold Nanorods for Targeted Photothermal Therapy of Neurotropic Virus Infection in the Mouse Brain